22. Moyamoya disease
11 clinical trials,   18 drugs   (DrugBank: 11 drugs),   28 drug target genes,   43 drug target pathways

Searched query = "Moyamoya disease", "Occlusive disease in circle of Willis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1ChiCTR2000029878
2020-11-012020-02-16The effects of norepinephrine and phenylephrine on cerebral oxygenation in treating intraoperative hypotension in STA-MCA bypass surgeryThe effects of norepinephrine and phenylephrine on cerebral oxygenation in treating intraoperative hypotension in STA-MCA bypass surgery moyamoya diseaseGroup 1:iv norepinephrine;Group 2:iv phenylephrine;The South District of Anhui Provincial HospitalNULLPending1865BothGroup 1:30;Group 2:30;Phase 4China
2NCT04205578
(ClinicalTrials.gov)
January 202018/12/2019NBP in Patients With Moyamoya Disease of High Risk for Ischemic Cerebrovascular EventsA Multi-center, Randomized, Single-blind, Placebo-controlled Study of Dl-3-n-butylphthalide in Patients With Moyamoya Disease of High Risk for Ischemic Cerebrovascular Events After Extracranial-to-intracranial Revascularization SurgeryMoyamoya Disease;Ischemic Cerebral Infarction;Ischemic Stroke;Ischemic Cerebrovascular Accident;Transient Ischemic AttackDrug: dl-3-n-butylphthalide (NBP);Drug: Normal Saline 0.9% Infusion Solutionyuanli ZhaoPeking University International HospitalNot yet recruiting18 Years60 YearsAll450Phase 3China
3ChiCTR1900027197
2019-05-012019-11-04Study on the protective effect of desflurane combined with propofol on the brain of patients with moyamoya disease undergoing cerebral revascularizationStudy for the protective effect of desflurane on the brain of patients with moyamoya disease moyamoya diseaseGroup D:Desflurane for anesthesia maintenance;GroupP:propofol;GroupPD:desflurane and propofol;The First Affiliated Hospital of Zhengzhou UniversityNULLCompleted2065BothGroup D:30;GroupP:30;GroupPD:30;Phase 4China
4NCT03882060
(ClinicalTrials.gov)
April 8, 201912/3/2019Effect of Recombinant Human EPO on the Postoperative Neurologic Outcome in Pediatric Moyamoya PatientsThe Effect of Recombinant Human Erythropoietin on the Postoperative Neurologic Outcome in Pediatric Moyamoya Disease Patients - A Double Blind Randomized Controlled TrialMoyamoya Disease;Pediatrics;Cerebrovascular DisordersDrug: erythropoietin;Drug: Normal salineSeoul National University HospitalNULLRecruitingN/A18 YearsAll82N/AKorea, Republic of
5ChiCTR1800020377
2019-01-012018-12-27Aspirin in Moyamoya DiseaseThe Clinical Benefit and Risk of Oral Aspirin for Moyamoya Disease moyamoya diseaseCase series:Aspirin;Beijing Tiantan Hospital, Capital Medical UniversityNULLRecruiting860BothCase series:300;China
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6JPRN-jRCTs031180017
01/08/201807/09/2018Studies on the utility of simultaneous-multi-slice acquisition (SMS) dynamic susceptibility contrast-enhanced (DSC)MRI for the occulusive cerebrobascular diseaseStudies on the utility of simultaneous-multi-slice acquisition (SMS) dynamic susceptibility contrast-enhanced (DSC)MRI for the occulusive cerebrobascular disease - SMS DSC-MRI study for the occulusive cerebrobascular disease carotid artery stenosis, moyamoya diseaseIntravenous administration of gadobutrol (Gadovist, Bayer Schering Pharma, Berlin, Germany) is administered in the supine position, and high speed DSC-MRI scan by using SMS acquisition (temporal resolution of 0.5s) is carried out at the same time as injection of the contrast agent with an acquisition time of 70sec. The quantitative and qualitative comparison between reference data set (0.5s) and additional data sets with temporal resolution of 1.0s, 1.5s, and 2.0s generated from the reference data set, is performed.Aoki ShigekiBayer Yakuhin, Ltd;Bayer Yakuhin, LtdComplete>= 20age oldNot applicableBoth50N/AJapan
7NCT04012268
(ClinicalTrials.gov)
July 10, 20173/7/2019The Safety and Efficacy of RIC on Adult Moyamoya DiseaseThe Safety and Effect of Remote Ischemic Conditioning on Adult Moyamoya DiseaseMoyamoya DiseaseDevice: RIC;Drug: AspirinCapital Medical UniversityNULLCompleted18 Years60 YearsAll30N/AChina
8NCT02510586
(ClinicalTrials.gov)
August 201524/7/2015Sevoflurane and Hyperperfusion SyndromeEffect of Sevoflurane-induced Postconditioning on the Incidence of Postoperative Cerebral Hyperperfusion Syndrome After Revascularization Surgery in Adult Patients With Moyamoya DiseaseHyperperfusion Syndrome;Moyamoya DiseaseDrug: SevofluraneSeoul National University HospitalNULLNot yet recruiting18 YearsN/ABoth152N/ANULL
9JPRN-UMIN000008742
2012/09/0121/08/2012Studies on the effect of free radical scavenger Edaravone against postoperative hyper-perfusion syndrome after STA-MCA bypass surgery for adult moyamoya disease. moyamoya diseaseAdministration of edaravone from preoperative to postoperative day 7.Department of Neurosurgery, Hokkaido University Graduate School of MedicineNULLComplete: follow-up complete16years-oldNot applicableMale and Female32Not applicableJapan
10NCT03162588
(ClinicalTrials.gov)
May 1, 201018/5/2017Multiple Burrhole Therapy With Erythropoietin for Unstable MoyamoyaFeasibility Study of Multiple Burrhole Therapy Combined With Intravenous Erythropoietin Pretreatment for Unstable MoyamoyaIschemic Attack;Ischemic Stroke;Moyamoya Disease;Burr Hole;AngiogenesisDrug: erythropoietinAjou University School of MedicineNULLCompleted16 YearsN/AAll37Phase 1;Phase 2Korea, Republic of
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11NCT01419275
(ClinicalTrials.gov)
April 200916/8/2011Quantifying Collateral Perfusion in Cerebrovascular Disease-Moyamoya Disease and Stroke PatientsQuantifying Collateral Perfusion in Cerebrovascular Disease-Moyamoya Disease and Stroke PatientsCerebrovascular Accident;Moyamoya DiseaseDrug: Xenon contrast agent;Device: Magnetic Resonance ImagingStanford UniversityNULLCompletedN/AN/AAll126N/AUnited States